News & Updates

Show Multimedia Only

Singapore Specialists Discuss RSV Prevention Strategies

22 Jul 2026

Two experts in their field, Dr Shephali Tagore and Clinical Associate Professor Yung Chee Fu, share their perspectives on maternal respiratory syncytial virus (RSV) immunisation, parental awareness gaps, and the practical realities of integrating prevention into clinical care pathways.

Singapore Specialists Discuss RSV Prevention Strategies

22 Jul 2026

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

16 Jul 2026

Protecting infants against RSV begins before birth. At a Pfizer-sponsored symposium during ESCMID Global 2026, experts reviewed the latest evidence on maternal RSV immunization, including disease burden, effectiveness, safety, and implementation. Presentations by Professors Marta Nunes, Paolo Manzoni, and Dr Olivia Anselem highlighted how maternal vaccination protects against severe RSV disease in early infancy. Professor Beate Kampmann chaired the session.

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

16 Jul 2026

Tackling the increasing threat of MBL-producing pathogens and S. maltophilia: Key insights from ESCMID Global 2026

14 Jul 2026

Antimicrobial resistance (AMR) continues to challenge healthcare systems worldwide, with carbapenem-resistant Gram-negative infections among the most urgent clinical threats. At a symposium held during ESCMID Global 2026, Dr Subramanian Swaminathan (India), Dr Paula Ramírez (Spain), Prof Gian Maria Rossolini (Italy), Prof Garyfallia Poulakou (Greece), and Prof Michele Bartoletti (Italy) explored the epidemiology, diagnosis, and management of infections caused by metallo-β-lactamase (MBL)-producing organisms, with a particular focus on carbapenem-resistant Enterobacterales (CRE) and Stenotrophomonas maltophilia.

Tackling the increasing threat of MBL-producing pathogens and S. maltophilia: Key insights from ESCMID Global 2026

14 Jul 2026

‘For the Reasons that Matter’ Campaign spotlights adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines

06 Jun 2026

In conjunction with World Immunisation Week, observed in the last week of April, Pfizer, together with healthcare professionals, launched “For the Reasons that Matter”, a regional public awareness campaign to raise awareness of adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines.

‘For the Reasons that Matter’ Campaign spotlights adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines

06 Jun 2026

Addressing the vaping epidemic: Policy and clinical observations to facilitate cessation

29 May 2026

Vaping has emerged as a significant public health concern, with the WHO estimating over 100 million users globally in 2025, including approximately 15 million adolescents. Misleading marketing and social media advertisements have perpetuated misperceptions about the health risks of vaping, driving uptake particularly among adolescents and young adults. This paper reviews the current evidence, regulatory landscape, and clinical guidance, highlighting that regulatory interventions alone are insufficient, as the heterogeneity of regulatory environments across countries limits the applicability of blanket recommendations. A multipronged approach encompassing expanded pharmacotherapy options is needed. While no standardized vaping cessation guidelines exist, several countries are extrapolating from smoking cessation frameworks and expediting pharmacotherapy approvals, recognizing the urgency of addressing this growing epidemic.

Addressing the vaping epidemic: Policy and clinical observations to facilitate cessation

29 May 2026

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

07 May 2026

Direct oral anticoagulants (DOACs) are established as first-line therapy for acute venous thromboembolism (VTE), offering effective thromboprophylaxis with improved safety compared with vitamin K antagonists. [Blood Adv 2020;4693-4738] However, despite the widespread use of apixaban and rivaroxaban in clinical practice, a lack of direct randomised comparative evidence has historically limited clinicians’ ability to differentiate between these agents. The COBRRA trial fills this gap, representing the first head-to-head randomised controlled trial (RCT) comparing apixaban and rivaroxaban in patients with acute VTE. [N Engl J Med 2026;394:1051-1060]

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

07 May 2026

Dupilumab improves quality of life in atopic dermatitis: Evidence and real-world insights

30 Apr 2026

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus, recurrent eczema, and substantial impairment in quality of life (QoL). Affecting up to 20 percent of children and approximately 10 percent of adults in high-income countries, AD places a significant burden on patients and their families, impacting sleep, productivity, and psychosocial well-being. [Br J Dermatol 2021;184:304-309]

Dupilumab improves quality of life in atopic dermatitis: Evidence and real-world insights

30 Apr 2026

Product Highlight - MENQUADFI

29 Apr 2026

Meningococcal group A, C, W & Y conjugate vaccine solution for injection 0.5 mL

Product Highlight - MENQUADFI

29 Apr 2026

Real-world evidence positions nirsevimab ahead in infant RSV prevention

14 Apr 2026

Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.

Real-world evidence positions nirsevimab ahead in infant RSV prevention

14 Apr 2026

EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

23 Feb 2026

Two leading experts discussed the role of EGb 761^® and digital interventions for patients with mild cognitive impairment (MCI) and dementia, highlighting real-world evidence supporting these approaches, at the inaugural Singapore International SEACURE+Neurocognition Symposium 2025.

EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

23 Feb 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Singapore Specialists Discuss RSV Prevention Strategies

Singapore Specialists Discuss RSV Prevention Strategies

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Protecting infants against RSV from Day 1: Insights from ESCMID Global 2026

Tackling the increasing threat of MBL-producing pathogens and S. maltophilia: Key insights from ESCMID Global 2026

Tackling the increasing threat of MBL-producing pathogens and S. maltophilia: Key insights from ESCMID Global 2026

‘For the Reasons that Matter’ Campaign spotlights adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines

‘For the Reasons that Matter’ Campaign spotlights adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines

Addressing the vaping epidemic: Policy and clinical observations to facilitate cessation

Addressing the vaping epidemic: Policy and clinical observations to facilitate cessation

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

Apixaban vs rivaroxaban for acute VTE: Insights from 1st head-to-head randomised trial

Dupilumab improves quality of life in atopic dermatitis: Evidence and real-world insights

Dupilumab improves quality of life in atopic dermatitis: Evidence and real-world insights

Product Highlight - MENQUADFI

Product Highlight - MENQUADFI

Real-world evidence positions nirsevimab ahead in infant RSV prevention

Real-world evidence positions nirsevimab ahead in infant RSV prevention

EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits

EGb 761® and digital intervention for MCI and dementia: Translating real-world evidence into patient benefits